Trial · NCT05282121
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Change in HVPG From Baseline (Measured in mmHg) After 8 Weeks of Treatment | Patients With HBV - Avenciguat | -16.06 | Standard Error 6.66 | Percentage of change in HVPG | |
| Percentage Change in HVPG From Baseline (Measured in mmHg) After 8 Weeks of Treatment | Patients With HCV - Avenciguat | -5.81 | Standard Error 7.09 | Percentage of change in HVPG | |
| Percentage Change in HVPG From Baseline (Measured in mmHg) After 8 Weeks of Treatment | Patients With NASH With or Without T2DM - Avenciguat | 3.83 | Standard Error 4.25 | Percentage of change in HVPG | |
| Percentage Change in HVPG From Baseline (Measured in mmHg) After 8 Weeks of Treatment | Patients With NASH With T2DM - Avenciguat + Empagliflozin | 3.27 | Standard Error 5.08 | Percentage of change in HVPG | |
| Occurrence of a Response, Which is Defined as > 10% Reduction From Baseline HVPG (Measured in mmHg) After 8 Weeks of Treatment | Patients With HBV - Avenciguat | 9 | Count of participants | ||
| Occurrence of a Response, Which is Defined as > 10% Reduction From Baseline HVPG (Measured in mmHg) After 8 Weeks of Treatment | Patients With HCV - Avenciguat | 2 | Count of participants | ||
| Occurrence of a Response, Which is Defined as > 10% Reduction From Baseline HVPG (Measured in mmHg) After 8 Weeks of Treatment | Patients With NASH With or Without T2DM - Avenciguat | 9 | Count of participants | ||
| Occurrence of a Response, Which is Defined as > 10% Reduction From Baseline HVPG (Measured in mmHg) After 8 Weeks of Treatment | Patients With NASH With T2DM - Avenciguat + Empagliflozin | 4 | Count of participants | ||
| Occurrence of One or More Decompensation Events (i.e. Ascites, VH, and / or Overt HE) During the 8-week Treatment Period | Patients With HBV - Avenciguat | 1 | Count of participants | ||
| Occurrence of One or More Decompensation Events (i.e. Ascites, VH, and / or Overt HE) During the 8-week Treatment Period | Patients With HCV - Avenciguat | 0 | Count of participants | ||
| Occurrence of One or More Decompensation Events (i.e. Ascites, VH, and / or Overt HE) During the 8-week Treatment Period | Patients With NASH With or Without T2DM - Avenciguat | 4 | Count of participants | ||
| Occurrence of One or More Decompensation Events (i.e. Ascites, VH, and / or Overt HE) During the 8-week Treatment Period | Patients With NASH With T2DM - Avenciguat + Empagliflozin | 1 | Count of participants | ||
| Occurrence of CTCAE Grade 3 (or Higher) Hypotension or Syncope Based on Investigator Judgement, During the 8-week Treatment Period | Patients With HBV - Avenciguat | 0 | Count of participants | ||
| Occurrence of CTCAE Grade 3 (or Higher) Hypotension or Syncope Based on Investigator Judgement, During the 8-week Treatment Period | Patients With HCV - Avenciguat | 0 | Count of participants | ||
| Occurrence of CTCAE Grade 3 (or Higher) Hypotension or Syncope Based on Investigator Judgement, During the 8-week Treatment Period | Patients With NASH With or Without T2DM - Avenciguat | 0 | Count of participants | ||
| Occurrence of CTCAE Grade 3 (or Higher) Hypotension or Syncope Based on Investigator Judgement, During the 8-week Treatment Period | Patients With NASH With T2DM - Avenciguat + Empagliflozin | 1 | Count of participants | ||
| Occurrence of Discontinuation Due to Hypotension or Syncope During the 8-week Treatment Period | Patients With HBV - Avenciguat | 0 | Count of participants | ||
| Occurrence of Discontinuation Due to Hypotension or Syncope During the 8-week Treatment Period | Patients With HCV - Avenciguat | 0 | Count of participants | ||
| Occurrence of Discontinuation Due to Hypotension or Syncope During the 8-week Treatment Period | Patients With NASH With or Without T2DM - Avenciguat | 0 | Count of participants | ||
| Occurrence of Discontinuation Due to Hypotension or Syncope During the 8-week Treatment Period | Patients With NASH With T2DM - Avenciguat + Empagliflozin | 1 | Count of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05282121/results